#Nuclear Medicine Diagnostic (SPECT and PET) market Size
Link
The Global Nuclear Medicine Diagnostic (SPECT and PET) Market (2022-2028) report provides an overview of the development strategies and plans, as well as information regarding the manufacturing cycles and cost structures. Additionally, the report includes import/export utilization, organic market, revenue, and gross margins. The Nuclear Medicine Diagnostic (SPECT and PET) Market Research Report that identifies the leading manufacturers includes GE Healthcare ,Siemens Healthineers ,Philips Healthcare ,Mediso ,Spectrum Dynamics ,Bruker ,SurgicEye ,MIE ,MILabs
In addition, this report offers a quantitative and qualitative analysis of the primary drivers, constraints, opportunities, and challenges influencing the development of the global Nuclear Medicine Diagnostic (SPECT and PET) market. A comprehensive market analysis is provided in the report, together with revenue forecasts for the leading players. In addition, the Nuclear Medicine Diagnostic (SPECT and PET) market report provides information about sales growth in several countries and regions as well as a competitive landscape and specific company analyses. This report examines the prospects and trends of the Nuclear Medicine Diagnostic (SPECT and PET) Market, as well as the current market share, penetration of various kinds, technologies, applications, and geographical regions.
Get Sample PDF Brochure at: https://www.xcellentinsights.com/enquiry/sample/75648
Drivers and restraints of the global Nuclear Medicine Diagnostic (SPECT and PET) market
The report incorporates an analysis of the factors that contribute to the growth of the market. It includes trends, restraints, and drivers that either positively or negatively affect the market. Moreover, this section includes the scope of different segments and applications that may influence the market in the future. Information in this section is based on present trends and historic milestones. As part of this section, the volume of production for each type of product from 2022 to 2028 is also discussed. From 2022 to 2028, this section provides information on the production volume by region. The report contains price analyses for each product type from the year 2022 to 2028, for each manufacturer from 2022 to 2028, for each region from 2022 to 2028, and for the global price from 2022 to 2028.
A thorough assessment of the restraints presented in the report illustrates the contrast with drivers and provides an opportunity for strategic planning. In order to get hold of the lucrative opportunities that are available in the ever-growing market, considering the factors that overshadow the market growth is pivotal. In addition, insights into market experts’ opinions have been taken into consideration to better understand the market.
Inquire more and share questions if any before the purchase on this report at – https://www.xcellentinsights.com/enquiry/buying/75648
Global Nuclear Medicine Diagnostic (SPECT and PET) Market: Segment Analysis
There are specific segments in the research report by region (country), manufacturer, type, and application. Production for each type is provided for the forecast period of 2022 to 2028. In addition, the Consumption by Application segment includes consumption forecasts for the period from 2022 to 2028. It is important to understand the segments in order to identify various factors that contribute to the market’s growth.
A study of the Nuclear Medicine Diagnostic (SPECT and PET) market provides a detailed analysis of the product scope, market overview, opportunities, risks, driving factors, sales, and revenue. The Nuclear Medicine Diagnostic (SPECT and PET) market report also contains information on manufacturers, regions, types, applications, sales channels, distributors, traders, dealers, and research findings. The Nuclear Medicine Diagnostic (SPECT and PET) market report also covers many ups and downs in the market during the Covid-19 pandemic, as well as country or regional factors that have affected the global market.
Nuclear Medicine Diagnostic (SPECT and PET) Market Segments by Type:
SPECT
PET
Nuclear Medicine Diagnostic (SPECT and PET) Market Segments by Application:
Oncology
Cardiology
Neurology
Others
Direct Purchase at: https://www.xcellentinsights.com/checkout/75648
This study provides an overview of the Nuclear Medicine Diagnostic (SPECT and PET) market in terms of definitions, classifications, applications, and the industry chain structure. The report provides a comprehensive analysis of the Nuclear Medicine Diagnostic (SPECT and PET) market share in the global market, as well as development trends, competitive landscape analysis, and key regions development status. The development policies and plans as well as manufacturing processes and cost structures are discussed in this paper. Besides import/export consumption and supply and demand data, this report provides cost, price, revenue, and gross margins.
The information provided is derived from current trends and historical milestones. Also included in this section is an analysis of the volume of production on the global market and for each type from 2022 to 2028. The following section addresses the volume of production by region from 2022 to 2028. The report includes an analysis of pricing based on each type from 2022 to 2028, the manufacturer from 2022 to 2028, the region from 2022 to 2028, and the global price from 2022 to 2028.
Reasons to Purchase Nuclear Medicine Diagnostic (SPECT and PET) Market Report
Nuclear Medicine Diagnostic (SPECT and PET) Market Report provides both qualitative and quantitative analysis of the market based on the analysis of market segments involving both economic and noneconomic factors.
The report gives an overview of the market value (USD) for each segment and sub-segment within the Nuclear Medicine Diagnostic (SPECT and PET) industry.
According to the report, the fastest growing segment and region will dominate the market over the next few years.
A geographic analysis of the Nuclear Medicine Diagnostic (SPECT and PET) market, indicating the consumption of the product in each region and the factors that are affecting the market within each region.
The competitive landscape includes information about the market rankings of the major companies along with information regarding new services/products, partnerships, business expansions, and acquisitions of the companies profiled in the last five years.
Extensive profiles of major market players that include an overview of the company, company insights, and product benchmarking as well as SWOT analyses.
#Nuclear Medicine Diagnostic (SPECT and PET) market#Nuclear Medicine Diagnostic (SPECT and PET) market Size#Nuclear Medicine Diagnostic (SPECT and PET) market Share
0 notes
Text
Evaluating Market Size and Growth Potential in Diagnostic Imaging Market
Market Overview –
The diagnostic imaging market is anticipated to reach USD 49.66 billion by 2032, growing at a CAGR of 4.7% over the forecast period 2023-2032.
The Diagnostic Imaging Market encompasses a wide range of medical imaging technologies used to visualize internal body structures and diagnose various medical conditions. These imaging modalities include X-ray, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and nuclear medicine techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT).
The diagnostic imaging market is thriving, propelled by advancements in medical imaging technologies. Medical imaging plays a crucial role in disease detection, diagnosis, and treatment planning. With continuous innovation, such as AI integration and portable imaging devices, the market is witnessing sustained growth, meeting the increasing demand for accurate and efficient diagnostic solutions.
In recent years, the diagnostic imaging market has experienced significant growth globally due to several factors. Firstly, there has been increasing demand for diagnostic imaging procedures driven by factors such as aging populations, rising prevalence of chronic diseases, and advancements in imaging technology. Key players in this market include medical device manufacturers, imaging equipment suppliers, healthcare providers, and research institutions, collaborating to develop and commercialize innovative imaging solutions.
Moreover, advancements in imaging technology have led to the development of new imaging modalities with improved resolution, speed, and diagnostic accuracy. These advancements enable earlier detection of diseases, more precise treatment planning, and better monitoring of treatment response, ultimately leading to improved patient outcomes.
Additionally, there is growing interest in personalized imaging approaches tailored to individual patient characteristics, such as genetic profiles, disease stage, and treatment history. Personalized imaging techniques enable healthcare providers to optimize imaging protocols and treatment strategies based on each patient's unique needs, enhancing the efficacy and safety of medical imaging procedures.
Overall, the diagnostic imaging market presents opportunities for growth and innovation as it continues to evolve with advancements in technology and increasing demand for diagnostic imaging services worldwide. Efforts to develop new imaging modalities, improve imaging quality, and expand access to imaging services are essential for advancing healthcare practices and improving patient care.
Market Segmentation –
The global diagnostic imaging market has been segmented on the basis of product, source, and application.
Based on product type, the market has been divided into x-ray equipment, ultrasound imaging systems, nuclear imaging systems, magnetic resonance imaging (MRI), computed tomography (CT) scanners, and other products
The market, by application, has been segmented into gynecology, oncology, orthopedics, cardiology, gastroenterology, neurology, and other applications
The end-user segment has been further divided into hospitals and clinics, diagnostic centers, research institutes, and others.
Regional Analysis –
Regional analysis of the diagnostic imaging market is essential for understanding the adoption, trends, and dynamics of imaging modalities across different geographic regions. Diagnostic imaging plays a crucial role in healthcare by enabling the visualization of internal body structures for diagnosis, monitoring, and treatment planning. Factors such as healthcare infrastructure, reimbursement policies, and prevalence of diseases influence the demand for various imaging technologies in each region.
Developed regions like North America and Europe often lead in the adoption of advanced imaging modalities such as MRI, CT scans, and PET scans due to well-established healthcare systems, high healthcare spending, and early adoption of innovative medical technologies. In contrast, emerging economies in Asia-Pacific and Latin America are witnessing increasing demand for diagnostic imaging, driven by factors such as rising healthcare expenditure, improving access to healthcare services, and growing prevalence of chronic diseases. Additionally, variations in regulatory frameworks and cultural attitudes towards healthcare impact market dynamics and adoption rates across regions.
Conducting a comprehensive regional analysis enables stakeholders to identify market opportunities, tailor their marketing strategies, and address region-specific challenges such as regulatory compliance and market access. By understanding regional nuances, companies can optimize their market penetration efforts and better serve the diagnostic imaging needs of healthcare providers and patients worldwide.
Key Players –
The Diagnostic imaging company profiles include Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Carestream Health, Esoate SpA, GE Healthcare, Toshiba Medical Systems Corporation, FUJIFILM Holdings Corporation, Siemens Healthcare Private Limited, Hitachi Medical Systems, Hologic Inc., and Shimadzu Corporation.
Related Reports –
Macrolide Antibiotics
Spinal Traction
Performance Enhancing Drugs
Vasectomy
For more information visit at MarketResearchFuture
#Diagnostic Imaging Market#Diagnostic Imaging Market Size#Diagnostic Imaging Market Share#Diagnostic Imaging Market Growth#Diagnostic Imaging Market Trends
0 notes
Text
Global Nuclear Medicine Market Size, Trends, Analysis, Growth, Share, Industry Forecast, 2023-2030
Global Nuclear Medicine Market
The Global Nuclear Medicine Market was valued at US$ 5.97 Bn in 2022 estimated to reach US$ 11.59 Bn by 2030, with a CAGR of 8.33% from 2023-2030.
In the field of medicine known as nuclear medicine, numerous ailments such as cancer, cardiac disease, and neurological problems are diagnosed and treated using radioactive materials called radiopharmaceuticals. High-tech cameras allow medical personnel to monitor the radioactive tracers' progress. Additionally, two essential imaging modalities in nuclear medicine are single-photon emission computed tomography (SPECT) and positron emission tomography (PET).
Read More: https://qualiketresearch.com/reports-details/Global-Nuclear-Medicine-Market
Market Drivers
The availability of a strong product pipeline and supportive government programs to increase accessibility to nuclear medicine is anticipated to drive market growth in the coming years. Clinical trials are being conducted on several products, such as betalains, omburtamab, yttrium-90 microspheres, PNT2003, and 177Lu-PNT2002. The U.S. has a favorable reimbursement environment for radiopharmaceuticals is expected to stimulate market expansion.
In addition, therapy requirements for patients are growing improvements in disease diagnosis and therapy as well as the approval of novel nuclear medicine-based technologies. For instance, GE Healthcare announced in September 2021 the introduction of a unique scanner with a new automated workflow feature that delivers an excellent view of cardiac anatomy and pathology to aid physicians in selecting the best course of treatment for a patient.
Market Segmentation
The scope of the Global Nuclear Medicine Market covers segmentation based on Diagnostics, Therapeutics, Applications, and Region.
Based on Diagnostics, the market is segmented into Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET).
Based on Therapeutics, the market is classified into Alpha Emitters, Beta Emitters, and Brachytherapy.
Based on Applications, the market is bifurcated into Cardiology, Neurology, Oncology, and Other Applications.
Request A Sample: https://qualiketresearch.com/request-sample/Global-Nuclear-Medicine-Market/request-sample
Regional Analysis
The Global Nuclear Medicine Market is segmented into 5 main regions, namely, North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The primary market for nuclear medicine is North America.
The United States' booming healthcare industry, rising cancer rates, rising geriatric population, rise in product launches driving up radioisotope usage, and increased initiatives and investments in cutting-edge healthcare solutions for cancer treatment are all expected to contribute to the market's expansion. In the United States, funding for cancer illness research and treatment is likewise rising. The National Centre for Health Statistics (NCHS) of the Centres for Disease Control & Prevention (CDC) has produced data that estimates cancer-related investments might reach up to USD 7,176 million in 2021.
Key Developments
The Department of Nuclear Medicine at PSG Hospitals in Coimbatore, which is outfitted with cutting-edge technology for diagnosing cancer and other disorders, was opened in April 2022 by Health Minister Ma. Subramanian.
A program enabling nuclear medicine facilities the chance to become designated and certified Centres of Excellence in Radiopharmaceutical Therapy was introduced by SNMMI in February 2022. Strict regulatory, training, certification, experience, and performance standards will be met by the centers, resulting in optimal patient selection and radiopharmaceutical therapy outcomes.
Key Players
Mallinckrodt plc., General Electric Co., Medtronic, plc. (Covidien, acquired by Medtronic), Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., IBA Group, Bracco Imaging S.p.A, NTP Radioisotopes SOC Ltd., Advanced Accelerator Applications S.A.
Key Questions Addressed by the Report
• What are the Key Opportunities in Global Bonsai Market?
• What will be the growth rate from 2023 to 2030?
• Which segment/region will have the highest growth?
• What are the factors that will impact/drive the Market?
• What is the competitive Landscape in the Industry?
• What is the role of key players in the value chain?
About Us:
QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers.
QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence.
QualiKet Research strive hard to simplify strategic decisions enabling you to make right choice. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. Our experts provide deep insights which is not available publicly that enables you to take bold steps.
Contact Us:
6060 N Central Expy #500 TX 75204, U.S.A
+1 214 660 5449
1201, City Avenue, Shankar Kalat Nagar,
Wakad, Pune 411057, Maharashtra, India
+91 9284752585
Sharjah Media City , Al Messaned, Sharjah, UAE.
+91 9284752585
0 notes
Text
Nuclear Medicine Market Segment Analysis By Product, Application, End-Use, Region And Forecast Till 2030: Grand View Research Inc.
San Francisco, 17 Nov 2023: The Report Nuclear Medicine Market Size, Share & Trends Analysis Report By Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy)), By Application, By End-use, By Region, And Segment Forecasts, 2023 – 2030
The global nuclear medicine market size is expected to reach USD 22.3 billion by 2030, registering a CAGR of 11.8% over the…
View On WordPress
#Nuclear Medicine Industry#Nuclear Medicine Market#Nuclear Medicine Market 2023#Nuclear Medicine Market 2030#Nuclear Medicine Market Revenue#Nuclear Medicine Market Share#Nuclear Medicine Market Size
0 notes
Text
Medical Imaging Equipment Market Size Expected To Acquire USD 48,786.03 million By 2030 At CAGR of 5.60%
The latest market report published by Credence Research, Inc. “Global Medical Imaging Equipment Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2030. The market for medical imaging equipment has been expanding steadily in recent years, and between 2023 and 2030, it is anticipated to rise at a CAGR of 5.60%. The market was estimated to be worth USD 31,548.9 million in 2022, and it is anticipated to be worth USD 48,786.03 million in 2030.
Medical Imaging Equipment Market Overview:
The Medical Imaging Equipment Market refers to the global industry that produces and sells various devices used to create visual representations of the interior of a body for clinical analysis and medical intervention. These devices play a crucial role in diagnosing, monitoring, and treating various medical conditions by providing valuable insights into the structure and functioning of internal organs and tissues. The market includes a wide range of imaging modalities, each with its own technology and applications.
Types of Medical Imaging Equipment:
Computed Tomography (CT) Scanners: CT scanners use a series of X-ray images taken from different angles to create detailed cross-sectional images of the body. They are especially useful for visualizing internal structures in 3D.
Magnetic Resonance Imaging (MRI) Systems: MRI uses strong magnetic fields and radio waves to generate detailed images of soft tissues, organs, and the nervous system. It's particularly valuable for diagnosing neurological and musculoskeletal conditions.
Ultrasound Machines: Ultrasound imaging uses high-frequency sound waves to create images of internal structures. It's commonly used for monitoring pregnancies, examining organs, and guiding procedures.
Nuclear Medicine Equipment: This category includes equipment like Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scanners. These technologies use radioactive tracers to visualize organ function and metabolism.
Partnerships and Collaborations:
Siemens Healthineers and Novartis: Siemens Healthineers entered into a partnership with Novartis to develop and commercialize assays measuring blood levels of certain therapeutic drugs using Siemens' Atellica Solution immunoassay analyzer. This collaboration aimed to enhance personalized treatment and monitoring of patients.
Philips and B. Braun Melsungen: Philips and B. Braun Melsungen collaborated in 2020 to provide an integrated regional solution for continuous ultrasound-guided regional anesthesia. The collaboration aimed to improve patient care during surgery by combining B. Braun's regional anesthesia expertise with Philips' ultrasound technology.
GE Healthcare and Roche: GE Healthcare and Roche collaborated in 2020 to develop and market digital diagnostics solutions, combining Roche's expertise in in-vitro diagnostics with GE Healthcare's expertise in medical imaging and monitoring.
Acquisitions:
Philips Acquires BioTelemetry: Philips acquired BioTelemetry, a company specializing in remote cardiac diagnostics and monitoring. This acquisition aimed to expand Philips' remote patient monitoring offerings and enhance its digital healthcare solutions.
Siemens Healthineers Acquires Varian Medical Systems: Siemens Healthineers completed the acquisition of Varian Medical Systems, a company known for its advanced radiation therapy solutions for cancer treatment. This acquisition aimed to strengthen Siemens Healthineers' oncology portfolio.
Canon Medical Systems Acquires Delft Imaging Systems: Canon Medical Systems acquired Delft Imaging Systems, a company focused on providing medical imaging solutions for low-resource settings. This acquisition aimed to enhance Canon's efforts to provide healthcare solutions to underserved regions.
Browse 240 pages report By End-User (Hospitals, Diagnostic Imaging Centers, Specialty Clinics, Ambulatory Care Centers) By Technology (Digital Imaging, Analog Imaging, 3D and 4D Imaging, Portable and Point-of-Care Imaging) By Specialty and Advanced Features Contrast-Enhanced Imaging, Functional Imaging, Interventional Imaging, Molecular Imaging) Growth, Future Prospects & Competitive Analysis, 2016 – 2030 - https://www.credenceresearch.com/report/medical-imaging-equipment-market
Here are some of the significant growth factors:
Technological Advancements: Continuous advancements in medical imaging technology, such as MRI, CT scans, ultrasound, and X-ray systems, have played a pivotal role in market growth. Improved imaging quality, faster scans, and reduced radiation exposure have expanded the applications and adoption of these technologies.
Aging Population: The global population is aging, leading to an increased demand for medical imaging services. As people age, they are more likely to require medical imaging for diagnostic purposes and disease management.
Rising Chronic Diseases: The prevalence of chronic diseases such as cancer, cardiovascular diseases, and orthopedic conditions is on the rise. These conditions often require diagnostic imaging for accurate diagnosis and treatment planning.
Emerging Markets: Developing countries are expanding their healthcare infrastructure, increasing access to medical imaging services. This has led to a significant market growth in regions like Asia-Pacific, Latin America, and the Middle East.
Why to Buy This Report-
The report provides a qualitative as well as quantitative analysis of the global Medical Imaging Equipment Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.
Major nations in each region with their import/export statistics
The global Medical Imaging Equipment Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/medical-imaging-equipment-market
Visit: https://www.credenceresearch.com/
Related Report: https://www.credenceresearch.com/report/ambulatory-surgery-centers-market
https://www.credenceresearch.com/report/veterinary-surgical-sutures-market
Browse Our Blog: https://www.linkedin.com/pulse/medical-imaging-equipment-market-grow-steadily-over-cagr-shukla
About Us -
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Contact Us:
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India
0 notes
Text
Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2028
The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market.
What’s keeping:
Cardinal Health (United States)
GE Healthcare (United States)
Curium (France)
Lantheus Medical Imaging (United States)
Bayer AG (Germany)
Bracco Imaging (Italy)
Eczacýbaþý-Monrol Nuclear Products (Turkey)
Nordion (Canada)
Advanced Accelerator Applications (France)
NTP Radioisotopes (South Africa)
Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.
The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360
On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99
Market Challenges: Hospital budget cuts and high equipment costs
Market Opportunities: Use of radiopharmaceuticals in neurological applications
Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions
Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments
Presented By
AMA Research & Media LLP
0 notes
Text
Nuclear Medicine/Radiopharmaceuticals Market – Trends Forecast Till 2028
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), Application (Oncology, Cardiology), Procedures and Region (North America, Europe, Asia-Pacific, Middle East and Africa and South America)
The Nuclear Medicine/Radiopharmaceuticals Market size is projected to reach a CAGR of 10.1% from 2021 to 2028.
Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.
Increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99 are some of the factors that have supported long-term expansion for Nuclear Medicine/Radiopharmaceuticals Market.
Request For Free Sample Report: https://www.delvens.com/get-free-sample/radiopharmaceuticals-market-trends-forecast-till-2028
Regional Analysis
North America is expected to account for the largest share of the nuclear medicine market during the forecast period, The large share of North America can be attributed to the development of novel technologies for radioisotope production, government funding, increasing R&D expenditure and company initiatives in the region.
Key Players
Mallinckrodt plc.
General Electric Co. (healthcare division)
Medtronic, Inc.
Bayer AG
Cardinal Health, Inc.
Lantheus Medical Imaging, Inc.
IBA Group
Make an Inquiry Before the Purchase: https://www.delvens.com/Inquire-before-buying/radiopharmaceuticals-market-trends-forecast-till-2028
Recent Developments
In 2021, Bracco entered into a partnership with CardioNavix which will help improve patient access to cardiac PET imaging.
In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.
Reasons to Acquire
Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
Gain authentic and granular data access for Nuclear Medicine/Radiopharmaceuticals Market so as to understand the trends and the factors involved behind changing market situations
Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns
Purchase This Report At: https://www.delvens.com/checkout/radiopharmaceuticals-market-trends-forecast-till-2028
Report Scope
Nuclear Medicine/Radiopharmaceuticals Market is segmented into type, application, procedural volume assessment and region.
On the basis of Type
Diagnostic Nuclear Medicine
Therapeutic Nuclear Medicine
Brachytherapy Isotopes
On the basis of Application
Diagnostic Applications
On the basis of Procedural Volume Assessment
Diagnostic Procedures
Therapeutic Procedures
On the basis of Region
Asia Pacific
North America
Europe
South America
Middle East & Africa
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact Us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-8638-5055
0 notes
Text
Radiopharmaceuticals Market
The “Radiopharmaceuticals Market” size was valued at USD 6,242.80 million in 2021 and is estimated to reach a compound annual growth rate CAGR of 6.2% over the forecast period 2023 to 2030. Radiopharmaceuticals are a class of pharmaceutical medicines with a significant radioactivity level. Radiopharmaceuticals are pharmaceuticals formulations that contain radioactive isotopes. These medications can be administered intravenously, orally, or interstitially. In addition, compared to X-rays and other external radiation imaging systems, it is a suitable and secure alternative for patients and aids physicians in diagnosis.
Radiopharmaceuticals and nuclear medicine are increasingly utilized in diagnostic imaging and radiotherapy. This has paved the way for the market expansion of radiopharmaceuticals. Nuclear medicine and radiopharmaceuticals aid in diagnosing organs affected by any pathological condition, particularly malignancy. This modality's applications have expanded from oncology to cardiology, neurology, and infection detection due to the rapid development of nuclear imaging technologies, particularly PET/PET-CT.
To Get a Free Sample Click here
Radiopharmaceuticals Market Dynamics:
Drivers:
The radiopharmaceuticals market is driven by several factors, including:
Increasing prevalence of cancer: With the rising incidence of cancer, the demand for radiopharmaceuticals is increasing as they are used in cancer diagnosis, staging, and treatment.
Growing demand for nuclear medicine: Radiopharmaceuticals are an essential part of nuclear medicine, which is increasingly being used for the diagnosis and treatment of various diseases.
Technological advancements in imaging modalities: The development of new imaging modalities, such as PET/CT and SPECT/CT, is driving the demand for radiopharmaceuticals, as these modalities require the use of radiopharmaceuticals.
Favorable regulatory policies: Governments are implementing favorable policies and regulations to promote the use of radiopharmaceuticals in healthcare, which is driving the growth of the market.
Increasing investment in research and development: Pharmaceutical companies are investing heavily in research and development to develop new radiopharmaceuticals and improve the existing ones, which is driving the growth of the market.
Rising geriatric population: With the increasing geriatric population, the incidence of chronic diseases is on the rise, which is driving the demand for radiopharmaceuticals in diagnosis and treatment.
Growing awareness about the benefits of nuclear medicine: As the awareness about the benefits of nuclear medicine and radiopharmaceuticals is increasing among patients and healthcare professionals, the demand for these products is also increasing.
Restraints:
Side-Effects of Radiopharmaceuticals
Numerous adverse effects of radiopharmaceuticals inhibit market expansion. Among the side effects are chills, severe lethargy, difficulty breathing, flushing or redness of the skin, nausea or vomiting, skin rash, hives, itching, severe headache, and abdominal pain. Therefore, these factors inhibit market expansion.
This radiopharmaceuticals market report provides details of new developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographies served, and competitive landscape. For more information on the radiopharmaceuticals market, contact Data Bridge Market Research for an Analyst Brief; our team will assist you in making well-informed decisions for market expansion.
Opportunities:
Increasing Demand for Nuclear Imaging Technologies
The development of nuclear imaging technologies, such as PET or PET-CT, has aided in expanding the applications of this modality from oncology to cardiology, neurology, and infection detection. These technological advances have significantly increased the number of PET and SPECT procedures. In the United States, approximately 2,220,300 PET treatments were performed in 2020, up from 2,200,800 in 2019. Consequently, it is anticipated that this factor will increase radiopharmaceutical market revenue.
Growing R&D Activities Associated with Radiopharmaceuticals
Increased radiopharmaceutical-related R&D activities enhanced market growth. In 2022, for example, the first patient dosed in phase III clinical trials for PET radiopharmaceutical imaging agents developed by GE Healthcare was initiated. The strategic approach will help to enhance patient care by identifying adult Parkinson's disease with greater precision. GE Healthcare will expand its radiation patent portfolio. Thus, this factor stimulates market expansion.
Market Segmentation Analysis:
The global Radiopharmaceuticals Market” is Segmented by Radioisotopes, Application, Source, End-user, and Region.
By Radioisotopes
Tec.99
F18
Iodine 131
Lutetium 177
Yttrium 90
Gallium 68
Gallium 67
Rubidium 82
Iodine 123
Iodine 125
Indium 111
Others
By Application
Oncology
Cardiology
Gastroenterology
Neuroendocrinology
Neurology
Nephrology
Others
By Source
Cyclotrons
Nuclear Reactor
By End User
Hospitals
Diagnostic Imaging Centers
Ambulatory Surgical Centers
Cancer Research Institute
By Region:
North America
Latin America
Europe
Asia Pacific
Middle East, and Africa
Competitive Landscape:
The radiopharmaceuticals market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are
Siemens AG
Positron Corporation
Curium
GE Healthcare
Lantheus Holdings Inc.
Sotera Health LLC
Bayer AG
Eckert & Ziegler
Novartis AG, and BWX Technologies Inc.
The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, which are contributing to the growth of the radiopharmaceutical market globally.
Siemens AG
Siemens is a technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In addition, Siemens holds a minority stake in Siemens Energy, a global leader in the transmission and generation of electrical power.
Recent Development
In 2021, NorthStar Medical Radioisotopes, LLC, a global radiopharmaceutical developer, and GE Healthcare confirmed an exclusive partnership to manufacture and distribute iodine-123 (I-123) capsules in the U.S. The product will assist GE Healthcare in enhancing its product portfolio and boosting its market position.
In 2021, Noria Therapeutics Inc. and PSMA Pharmaceuticals Inc. were acquired by Bayer AG Targeted both radiotherapy businesses are developing therapeutic and diagnostic radiopharmaceuticals. The acquisition is anticipated to add to Bayer's current nuclear medicine oncology portfolio.
Regional Analysis:
North America dominates the radiopharmaceuticals market because of the huge base of healthcare facilities and increasing overweight population base. Also, wide presence of a huge patient population suffering from chronic diseases such as coronary disorders, cancer, and strokes and rising number of research activities in this region are also boosting the market growth.
Asia-Pacific is expected to witness significant growth due to the growth in government initiatives to raise awareness and increasing research activities in the region. Also, growing availability of the well-established infrastructure, wide presence of major market players, growth in cases of cardiovascular diseases are boosting the growth rate of the market.
About DataM Intelligence:
DataM Intelligence 4Market Research is a market intelligence platform that gives access to syndicated, customized reports and consulting to its clients in one place. As a firm with rich experience in research and consulting across multiple domains, we are a one-stop solution that will cater to clients' needs in crucial business areas. DataM Intelligence has an online platform covering industries such as chemicals and materials, agriculture, health care services, animal feed, and food & beverages, among others. Our forum has Insights on markets that uncover the latest market research data distinct from the competition. With coverage across ten major industries in the marketplace research, DataM Intelligence benefits thousands of companies by helping them take their innovations early to the Market by providing a complete view of the Market with statistical forecasts. Our strategy-centric framework and value-added services will let individuals and corporates ease access and custom personalization to research and markets.
Contact Us:
For more information: Sai Kiran
Sales Manager at DataM Intelligence
Email: [email protected]
Tel: +1 877 441 4866
Website: www.datamintelligence.com
0 notes
Text
what is Nuclear Medicine or Radiopharmaceuticals Market?
Nuclear Medicine or Radiopharmaceuticals Market size is projected to reach USD 9.52 Billion by 2028 from an estimated USD 5.70 Billion in 2021, growing at a CAGR of 7.6% globally.
The "Global Nuclear Medicine or Radiopharmaceuticals Market by Type, Application and Region - Forecast to 2028" report has been added to Introspective Market Research offering. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment prices are expected to limit market growth to a certain extent.
In this report, the nuclear medicine market has been segmented based on type, application, procedure volume and region. Based on type, the nuclear medicine market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes. The diagnostic nuclear medicine segment is segmented into SPECT and PET.
Key Prominent Players In The Nuclear Medicine or Radiopharmaceuticals Market:
· Actinium Pharmaceuticals Inc. (US)
· Alliance Medical (UK)
· Avid Bioservices Inc (US)
· Bayer HealthCare Pharmaceuticals (Germany)
· Bracco Diagnostics Inc. (Italy)
· Cardinal Health Inc. (US)
· GE Healthcare (US)
· Ion Beam Applications S.A (Belgium)
· Jubilant Pharma (India)
· Lantheus Medical Imaging Inc. (US)
· Medi-Radiopharma Ltd (Hungary)
· Nordion Inc. (Canada)
· Novartis/Advanced Accelerator Applications (France)
· Positron Corporation (US)
· Radiopharm Theranostics Ltd. (US)
Know More About The Global Trends Impacting The Future, Download A PDF Sample@:https://www.introspectivemarketresearch.com/request/15924
Market segmentation
The Nuclear Medicine or Radiopharmaceuticals market is segmented by type and application. Growth between segments over the period 2022-2028 provides accurate calculations and forecasts of revenue by type and application in terms of volume and value. This analysis can help you expand your business by targeting eligible niches.
Nuclear Medicine or Radiopharmaceuticals Market Segment by Types, Estimates, and Forecast by 2028
Diagnostic,Therapeutic,Research
Nuclear Medicine or Radiopharmaceuticals Market Segment by Applications, Estimates, and Forecast by 2028
Oncology,Thyroid,Cardiology,Neurology and Others
Regional Analysis for COVID-19 Outbreak-Global Nuclear Medicine or Radiopharmaceuticals Market:
APAC (Japan, China, South Korea, Australia, India, and Rest of APAC)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
North America (U.S., Canada, and Mexico)
South America (Brazil, Chile, Argentina, Rest of South America)
MEA (Saudi Arabia, UAE, South Africa)
We Offer Discount on The Nuclear Medicine or Radiopharmaceuticals Market Report @: https://www.introspectivemarketresearch.com/discount/15924
Industry experts have identified key factors influencing the pace of development of the Nuclear Medicine or Radiopharmaceuticals industry, including various opportunities and gaps. A thorough analysis of the Nuclear Medicine or Radiopharmaceuticals market for the growth trends of each category makes the overall study interesting. When studying the market, researchers also dig deep into their future prospects and their contribution to the industry. Additionally, the research report evaluated the market key players and features, such as capacity utilization rate comprised of revenue.
Nuclear Medicine or Radiopharmaceuticals Report provides insights into the following queries:
1.Market growth rate and growth momentum of Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028
2. The estimated size of the Nuclear Medicine or Radiopharmaceuticals market for the period 2022-2028
4. Sales (volume), revenue, and value analysis by regions of Nuclear Medicine or Radiopharmaceuticals market
5. The associated market risk, opportunity, and market overview of the Nuclear Medicine or Radiopharmaceuticals market
6. Major distributors, dealers, end-users, and traders of the Nuclear Medicine or Radiopharmaceuticals market?
Make An Inquiry For Report Customization (Must Use Business Contact Details For High Preference):https://www.introspectivemarketresearch.com/inquiry/15924
This study conducts a SWOT analysis to evaluate the strengths and weaknesses of key players in the Nuclear Medicine or Radiopharmaceuticals market. Additionally, the report performs a complex inspection of drivers and restraints operating in the market. The report also evaluates the observed trends in the parent market along with macroeconomic indicators, dominant factors and market attractiveness in relation to other segments. The report forecasts the impact of various industry aspects on the Nuclear Medicine or Radiopharmaceuticals market segments and regions.
Key Points Covered in Radiopharmaceuticals Market Study
· Market estimates and forecast 2022-2028
· Key drivers and restraints impacting market growth
· Segment-wise, Country-wise, and Region-wise Analysis
· Competition Mapping and Benchmarking
· Brand share and Market Share Analysis
· Key Radioisotope Innovations and Regulatory Climate
· COVID-19 Impact on Radiopharmaceuticals market and How to Navigate
· Recommendation on Key Winning Strategies
0 notes
Text
The nuclear medicine and radiopharmaceutical manufacturing market is estimated to be more than USD 6 billion in 2030
The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals
Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030”
The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:
§ A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals.
§ An insightful four-dimensional comparison of the radiopharmaceutical manufacturers.
§ Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players).
§ An analysis of recent partnerships and collaborations inked in this domain since 2017.
§ A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m).
§ A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
§ Target Therapeutic Area
§ Cardiology
§ Neurology
§ Oncology
§ Thyroid
§ Others
Application Area
§ Diagnostic
§ Therapeutic
§ Type of Diagnostic Radiopharmaceuticals
§ PET
§ SPECT
§ Type of Therapeutic Radiopharmaceuticals
§ Alpha Emitters
§ Beta Emitters
§ Others
§ Purpose of Production
§ In-House
§ Outsourcing
Key Geographical Region
§ North America
§ Europe
§ Asia-Pacific and the Rest of the World
Transcripts of interviews held with the following senior level representatives of stakeholder companies
§ J James Davis, Vice President Quality / R&D, Shertech Laboratories
§ Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School
§ Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen
§ Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
§ Anonymous, ITM Isotopen Technologien München
Key companies covered in the report
§ Advanced Accelerator Applications
§ Belgian Nuclear Research Center (SCK•CEN)
§ Cardinal Health
§ China Isotope & Radiation Corporation
§ Curium Pharma
§ DuChemBio
§ Eckert & Ziegler
§ Eczacibasi-Monrol
§ GE Healthcare
§ Jubilant DraxImage
§ Lantheus Medical Imaging
§ Nihon Medi-Physics
§ Nordion
§ PETNET Solutions
§ SinoTau Pharmaceuticals
§ SOFIE
For more information please click on the following link:
https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing.html
Other Recent Offerings
1. High Energy Chemistry / Hazardous Chemistry-based API Manufacturing Services Market: Focus on High Temperature, Low Temperature / Cryogenic, High Pressure and Low Pressure Chemistries, 2020-2030
2. Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030
3. China Biopharmaceutical Contract Manufacturing Market, 2020 - 2030
4. Continuous Manufacturing Market (Small Molecules and Biologics), 2020 – 2030
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at [email protected]
Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
0 notes
Text
Global North American Nuclear Medicine Market : Global Analysis, Opportunities And Forecast - 2024
[159 Pages Report] The North American nuclear medicine market is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period.
The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.
Market Dynamics
Increasing Incidence and Prevalence of Target Conditions
Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
Initiatives to Lessen the Demand-Supply Gap of Mo-99
The increasing adoption of automated inspection systems in the pharmaceutical and biotechnology industries, growth in the number of product recalls, an increasing number of inspection checkpoints throughout the production line, and technological advancements in inspection systems support the growth of the market.
Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1108
Based on type, the market is categorized into diagnostic and therapeutic nuclear medicine. The therapeutic nuclear medicine segment is further segmented into alpha emitters, beta emitters, and brachytherapy isotopes.
The geographical regions mapped in the report are:
1. North America
2. US
3. Canada
Geographically, the North American market comprises of US and Canada. In 2018, the US accounted for the largest share of the nuclear medicine market. The large share can be attributed to the development of novel technologies for radioisotope production, government funding, and company initiatives in the country.
Based on application, the North American nuclear medicine market is segmented into SPECT, PET, and therapeutic applications. The SPECT applications segment is further segmented into cardiology, bone scans, thyroid applications, pulmonary scans, and other SPECT applications. The thyroid applications segment is projected to register the highest growth rate in the forecast period. The high growth of this segment can be attributed to the increasing incidence and prevalence of thyroid disorders.
Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=1108
0 notes
Text
Neurodiagnostics Market 2024 Rising Demand | Opportunities, Future Scope, Market Status
7th January 2022 – The global Neurodiagnostics Market is anticipated to reach at USD 18.3 billion by 2024. Neurodiagnostics are also known as “Neurodiagnostic tests”. They diagnose neurological disorders such as migraine, Parkinson’s disease, stroke, ischemic stroke and epilepsy. The factors that propel the growth of the Neurodiagnostics Market include increasing occurrence of neurological disorders such as stroke, growing consciousness among people and technological developments. On the other hand, there are factors that may hamper the growth of the market including lack of mental health checkup & regular diagnosis in emerging countries. Neurodiagnostics industry is anticipated to grow at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe.
The market may be explored by product type, end users, technology, and geography. The industry may be explored by product type as intracranial pressure monitor, Electromyography (EMG), Electroencephalogram (EEG), Transcranial Doppler, and Cerebral oximeters. The “Electroencephalogram (EEG)” segment led the Neurodiagnostics Market in 2015 and is anticipated to maintain its dominance by 2024.The key factor that could be attributed to the growth of market includes capacity to efficiently diagnoze epilepsy and the other neurological disorders through non-invasive methods. Neurodiagnostics industry may be explored by technology as neuroimaging technologies that may further include Nuclear Medicine Imaging (SPECT, PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Electroencephalography (EEG), Near Infrared Spectroscopic Imaging (NIRS), Voxel-based Morphometry (VBM), and Magnetoencephalography (MEG) in vitro diagnostics, and neuroinformatic.
The “CT and MRI” segment led the neurodiagnostics industry in 2015 and is anticipated to maintain its dominance by 2024.The factors that could be attributed to the growth of the segment might include increasing adoption in the internal body surgeries. The market could be explored based on end users as hospitals, operation theatres, neurophysiological
laboratories and clinics. North America accounted for the major share of the Neurodiagnostics Market Size in 2015 and will continue to lead in the forecast period. The factors that could be attributed to the growth include increasing acceptance of neurodiagnostics technology.
Some of the key players that fuel the growth of the neurodiagnostics industry comprise Alpha Omega Ltd., Bruker, Guerbet, Agilent Technologies, Fonar Corporation, Doric Lenses, Inc., GE Healthcare, Hitachi Medical Corporation, Hologic Inc., Mightex Systems, NeuroNexus Technologies, Neusoft Medical Systems Co., Ltd., Roche Diagnostics, Plexon, Inc., Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.
Request a Sample Copy of Neurodiagnostics Market Report @ https://www.millioninsights.com/industry-reports/neurodiagnostics-market/request-sample
1 note
·
View note
Text
Neurodiagnostics Market Forecast Report 2024 by Size, Share, Revenue, Business Growth, Demand and Applications
7th January 2022 – The global Neurodiagnostics Market is anticipated to reach at USD 18.3 billion by 2024. Neurodiagnostics are also known as “Neurodiagnostic tests”. They diagnose neurological disorders such as migraine, Parkinson’s disease, stroke, ischemic stroke and epilepsy. The factors that propel the growth of the Neurodiagnostics Market include increasing occurrence of neurological disorders such as stroke, growing consciousness among people and technological developments. On the other hand, there are factors that may hamper the growth of the market including lack of mental health checkup & regular diagnosis in emerging countries. Neurodiagnostics industry is anticipated to grow at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe.
The market may be explored by product type, end users, technology, and geography. The industry may be explored by product type as intracranial pressure monitor, Electromyography (EMG), Electroencephalogram (EEG), Transcranial Doppler, and Cerebral oximeters. The “Electroencephalogram (EEG)” segment led the Neurodiagnostics Market in 2015 and is anticipated to maintain its dominance by 2024.The key factor that could be attributed to the growth of market includes capacity to efficiently diagnoze epilepsy and the other neurological disorders through non-invasive methods. Neurodiagnostics industry may be explored by technology as neuroimaging technologies that may further include Nuclear Medicine Imaging (SPECT, PET), Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Electroencephalography (EEG), Near Infrared Spectroscopic Imaging (NIRS), Voxel-based Morphometry (VBM), and Magnetoencephalography (MEG) in vitro diagnostics, and neuroinformatic.
The “CT and MRI” segment led the neurodiagnostics industry in 2015 and is anticipated to maintain its dominance by 2024.The factors that could be attributed to the growth of the segment might include increasing adoption in the internal body surgeries. The market could be explored based on end users as hospitals, operation theatres, neurophysiological
laboratories and clinics. North America accounted for the major share of the Neurodiagnostics Market Size in 2015 and will continue to lead in the forecast period. The factors that could be attributed to the growth include increasing acceptance of neurodiagnostics technology.
Some of the key players that fuel the growth of the neurodiagnostics industry comprise Alpha Omega Ltd., Bruker, Guerbet, Agilent Technologies, Fonar Corporation, Doric Lenses, Inc., GE Healthcare, Hitachi Medical Corporation, Hologic Inc., Mightex Systems, NeuroNexus Technologies, Neusoft Medical Systems Co., Ltd., Roche Diagnostics, Plexon, Inc., Philips Healthcare, Siemens Healthcare and Toshiba Medical Systems Corporation. The leading companies are taking up partnerships, mergers and acquisitions, and joint ventures in order to boost the inorganic growth of the industry.
Request a Sample Copy of Neurodiagnostics Market Report @ https://www.millioninsights.com/industry-reports/neurodiagnostics-market/request-sample
0 notes
Text
Biologic Imaging Reagents Market Size Worth USD 29.59 Billion, Globally, By 2030 At CAGR of 8.70%
The latest market report published by Credence Research, Inc. “Global Biologic Imaging Reagents Market: Growth, Future Prospects, and Competitive Analysis, 2016 – 2030. The global demand for biologic imaging reagents was valued at USD 16.5 Billion in 2022 and is expected to reach USD 29.59 Billion in 2030, growing at a CAGR of 8.70% between 2023 and 2030.
The Biologic Imaging Reagents Market refers to the segment of the healthcare and life sciences industry that focuses on the production, sale, and application of reagents used in imaging procedures related to biology and medicine. These reagents play a critical role in enhancing, facilitating, or making possible the visualization of biological processes, structures, and abnormalities at various scales, from the molecular to the organismal.
Here are some key aspects of the Biologic Imaging Reagents Market:
Types of Imaging Reagents: There are various types of imaging reagents based on the imaging modalities they're meant for. These include fluorescent dyes and probes for fluorescence microscopy, contrast agents for MRI (magnetic resonance imaging), radiolabeled compounds for PET (positron emission tomography) and SPECT (single-photon emission computed tomography), and more.
Applications: Biologic imaging reagents are used in a range of applications such as clinical diagnostics, drug discovery and development, basic research, and therapeutic monitoring. For instance, they might help visualize the progression of a disease, the delivery of a drug to its target, or the activity of a specific molecule within a cell.
Regulatory Concerns: Given that many of these reagents are used in clinical settings, they must undergo rigorous testing and approval by regulatory bodies (like the FDA in the US) to ensure their safety and efficacy.
Partnership and acquisition in Biologic Imaging Reagents Market
The Biologic Imaging Reagents Market has witnessed significant growth in recent years, owing to the increasing demand for bio-imaging techniques across various industries such as pharmaceuticals, biotechnology, and research organizations. To keep up with this rising demand and stay ahead in the competitive market, many companies are exploring partnership and acquisition strategies. These partnerships enable key players to leverage each other's strengths in terms of technology expertise, distribution networks, and customer base.
Additionally, acquisitions help businesses expand their product portfolios by integrating complementary offerings into their existing lineups. Through these collaborative efforts and strategic moves within the Biologic Imaging Reagents Market, companies aim to enhance their capabilities and provide innovative solutions that cater to a diverse range of application areas ranging from drug discovery to disease diagnosis and treatment monitoring. As a result, stakeholders can expect an accelerated pace of development in this dynamic industry sector.
Segmentation
By Class
Contrast Reagents
Optical Reagents
Nuclear Reagents
By Modality
MRI
Ultrasound
X-ray & CT
Nuclear
Optical Imaging
Others
Top Report Findings in Biologic Imaging Reagents Market
Biologic Imaging Reagents Market is a rapidly growing sector that has witnessed significant advancements in recent years, and the latest top report findings shed light on its current state. The market analysis highlights the increasing demand for biologic imaging reagents across various research fields, including cell biology, neuroscience, and immunology. Researchers are increasingly relying on these reagents to visualize specific molecules or cellular structures within living organisms at both macroscopic and microscopic levels.
This report reveals that the market is expected to witness substantial growth due to several factors such as the rising prevalence of chronic diseases requiring advanced diagnostic techniques, expanding applications of biologic imaging reagents in drug development, and technological innovations facilitating higher resolution imaging with improved sensitivity. Moreover, it emphasizes how strategic collaborations between academic institutions and pharmaceutical companies have further propelled market expansion by fostering research discoveries in disease mechanisms and potential therapeutic targets.
List of the prominent players in the Biologic Imaging Reagents Market:
Thermo Fisher Scientific
PerkinElmer Inc
Guerbet
Beckman Coulter Inc
Bracco Diagnostic Inc
Bayer
FUJIFILM VisualSonics Inc
General Electric
Browse 250 pages report - Biologic Imaging Reagents Market By Class (Contrast Reagents, Optical Reagents, Nuclear Reagents) By Modality (MRI, Ultrasound, X-ray & CT, Nuclear)- Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/biologic-imaging-reagents-market
Market Recommendations in Biologic Imaging Reagents Market
The Biologic Imaging Reagents Market has witnessed significant growth in recent years, owing to the rising demand for advanced imaging techniques for research and diagnostic purposes. As a result, market players are strategizing to tap into this lucrative opportunity by offering innovative solutions that cater to the specific needs of scientists and healthcare professionals. One key recommendation for companies operating in the Biologic Imaging Reagents Market is to invest heavily in research and development activities.
By doing so, they can stay ahead of their competitors and continuously introduce novel reagents that enhance imaging capabilities while maintaining high levels of accuracy and reliability. Additionally, collaborating with academic institutions or research organizations could prove beneficial as it provides access to cutting-edge discoveries in imaging technology and facilitates knowledge exchange between industry experts.
Furthermore, expanding product portfolios by acquiring smaller biotech firms or entering into strategic partnerships allows companies to diversify offerings and strengthens their position within the market. It would also be wise for businesses to focus on improving supply chain efficiencies, ensuring timely delivery of products while minimizing costs associated with storage and transportation. Lastly, given the increasing adoption of fluorescence-based imaging techniques, manufacturers should prioritize the development of fluorescent dyes with improved sensitivity and reduced toxicity profiles – ultimately enabling safer procedures without compromising image quality or patient comfort.
Why to Buy This Report-
The report provides a qualitative as well as quantitative analysis of the global Biologic Imaging Reagents Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.
The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.
Major nations in each region with their import/export statistics
The global Biologic Imaging Reagents Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.
Browse Full Report: https://www.credenceresearch.com/report/biologic-imaging-reagents-market
Visit: https://www.credenceresearch.com/
Related Report: https://www.credenceresearch.com/report/capsule-endoscope-and-workstation-market
https://www.credenceresearch.com/report/cell-separation-technologies-market
Browse Our Blog: https://www.linkedin.com/pulse/biologic-imaging-reagents-market-grow-steadily-over-cagr-shukla
About Us-
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Contact Us:
Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India
0 notes
Text
Radiopharmaceuticals in Nuclear Medicine Market to Eyewitness Massive Growth by 2027
The Latest Released market study on Global Radiopharmaceuticals in Nuclear Medicine market provides information and useful stats on market structure, size and trends. The report is intended to provide cutting-edge market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Besides, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Radiopharmaceuticals in Nuclear Medicine market.
What’s keeping:
Cardinal Health (United States)
GE Healthcare (United States)
Curium (France)
Lantheus Medical Imaging (United States)
Bayer AG (Germany)
Bracco Imaging (Italy)
Eczacýbaþý-Monrol Nuclear Products (Turkey)
Nordion (Canada)
Advanced Accelerator Applications (France)
NTP Radioisotopes (South Africa)
Keep Growing in the Market? Benchmark yourself with the strategic moves and latest Market Share and Sizing of Global Radiopharmaceuticals in Nuclear Medicine market recently published by AMA
Radiopharmaceuticals are radioactive compounds that have a bound radionuclide in their structure, whose purpose is directing the radionuclide to a location to be treated or to obtain images. Nuclear medications, also known as radiopharmaceuticals, are used to treat lymphoma and bone metastases. Nuclear medicines such as F-18, Tc-99, Ga-67, and I-123 are used in diagnostic operations, while I-131, Ir-192, Y-90, I-125, Lu-177, and Ra-223 are employed in therapeutic procedures. In comparison to chemotherapy, the convenience of treatment using minimally invasive approaches attracts more people to radiopharmaceuticals. The radiopharmaceuticals industry is driven by the rising number of cardiac patients and the development of clear imaging techniques using diagnostic equipment such as PET and SPECT. Supply constraints, logistical challenges, and a scarcity of skilled medical professionals are among the problems limiting the market's growth.
The Radiopharmaceuticals in Nuclear Medicine Market segments and Market Data Break Down 24360
On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
What’s Trending in Market: High Demand due to increasing Initiatives to reduce the demand and supply gap of Mo-99
Market Challenges: Hospital budget cuts and high equipment costs
Market Opportunities: Use of radiopharmaceuticals in neurological applications
Highlights of Influencing Drivers: Rising incidence as well as prevalence of target conditions
Huge Development of alpha-radioimmunotherapy-based targeted cancer treatments
Presented By
AMA Research & Media LLP
0 notes
Text
Radiopharmaceutical Market Size, Share With Top Companies, Region Forecast 2021-2027
Radiopharmaceutical Market 2020-2026
A New Market Study, Titled “Radiopharmaceutical Market Upcoming Trends, Growth Drivers and Challenges” has been featured on fusionmarketresearch.
Description
This global study of the Radiopharmaceutical market offers an overview of the existing market trends, drivers, restrictions, and metrics and also offers a viewpoint for important segments. The report also tracks product and services demand growth forecasts for the market. There is also to the study approach a detailed segmental review. A regional study of the global Radiopharmaceutical industry is also carried out in North America, Latin America, Asia-Pacific, Europe, and the Near East & Africa. The report mentions growth parameters in the regional markets along with major players dominating the regional growth.
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
Request a Free Sample Report @ https://www.fusionmarketresearch.com/sample_request/(COVID-19-Version)-Global-Radiopharmaceutical-Market-Status-(2015-2019)-and-Forecast-(2020-2025)-by-Region,-Product-Type-&-End-Use
The report offers detailed coverage of Radiopharmaceutical industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Radiopharmaceutical by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
First, this report covers the present status and the future prospects of the global Radiopharmaceutical market for 2015-2024.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
At the same time, we classify Radiopharmaceutical according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Finally, the report provides detailed profile and data information analysis of leading Radiopharmaceutical company.
Key Companies
Bayer
Triad Isotopes
Lantheus
GE Healthcare
Mallinckrodt
Eli Lilly
Bracco Imaging
SIEMENS
Navidea
Nordion
IBA Group
Jubilant Pharma
Market Segment as follows:
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
Market by Type
SPECT Radioisotopes
PET Radioisotopes
Other Diagnostic Radioisotopes
Therapeutic Radioisotopes
Market by Application
Oncology
Cardiology
Others
Ask Enquire @ https://www.fusionmarketresearch.com/enquiry.php/(COVID-19-Version)-Global-Radiopharmaceutical-Market-Status-(2015-2019)-and-Forecast-(2020-2025)-by-Region,-Product-Type-&-End-Use
Table of Contents
Part 1 Market Overview
1.1 Market Definition
1.2 Market Development
1.2.1 Current Situation
1.2.2 Aspects of COVID-19 Impact
1.3 By Type
Table Type of Radiopharmaceutical
Figure Global Radiopharmaceutical Market Share by Type in 2019
1.4 By Application
Table Application of Radiopharmaceutical
Figure Global Radiopharmaceutical Market Share by Application in 2019
1.5 By Region
Figure Global Radiopharmaceutical Market Share by Region in 2019
Figure Asia Radiopharmaceutical Market Share by Region in 2019
Part 2 Key Companies
2.1 Bayer
2.1.1 Company Profile
Table Bayer Overview List
2.1.2 Products & Services Overview
2.1.3 Sales Data List
Table Radiopharmaceutical Business Operation of Bayer (Sales Revenue, Sales Volume, Price, Cost, Gross Margin)
2.2 Triad Isotopes
2.3 Lantheus
2.4 GE Healthcare
2.5 Mallinckrodt
2.6 Eli Lilly
2.7 Bracco Imaging
2.8 SIEMENS
2.9 Navidea
2.10 Nordion
2.11 IBA Group
2.12 Jubilant Pharma
Part 3 Global Market Status and Future Forecast
3.1 Global Market by Region
Table Global Radiopharmaceutical Market by Region, 2015-2019 (Million USD)
Figure Global Radiopharmaceutical Market Share by Region in 2019 (Million USD)
Table Global Radiopharmaceutical Market by Region, 2015-2019 (Volume)
Figure Global Radiopharmaceutical Market Share by Region in 2019 (Volume)
Table Price List by Region, 2015-2019
3.2 Global Market by Company
Table Global Radiopharmaceutical Market by Company, 2015-2019 (Million USD)
Figure Global Radiopharmaceutical Market Share by Company in 2019 (Million USD)
Table Global Radiopharmaceutical Market by Company, 2015-2019 (Volume)
Figure Global Radiopharmaceutical Market Share by Company in 2019 (Volume)
Table Price List by Company, 2015-2019
3.3 Global Market by Type
Table Global Radiopharmaceutical Market by Type, 2015-2019 (Million USD)
Figure Global Radiopharmaceutical Market Share by Type in 2019 (Million USD)
Table Global Radiopharmaceutical Market by Type, 2015-2019 (Volume)
Figure Global Radiopharmaceutical Market Share by Type in 2019 (Volume)
Table Price List by Type, 2015-2019
3.4 Global Market by Application
Table Global Radiopharmaceutical Market by Application, 2015-2019 (Million USD)
Figure Global Radiopharmaceutical Market Share by Application in 2019 (Million USD)
Table Global Radiopharmaceutical Market by Application, 2015-2019 (Volume)
Figure Global Radiopharmaceutical Market Share by Application in 2019 (Volume)
Table Price List by Application, 2015-2019
3.5 Global Market by Forecast
Figure Global Radiopharmaceutical Market Forecast, 2020-2025 (Million USD)
Figure Global Radiopharmaceutical Market Forecast, 2020-2025 (Volume)
….
Part 9 Market Features
9.1 Product Features
9.2 Price Features
9.3 Channel Features
9.4 Purchasing Features
Part 10 Investment Opportunity
10.1 Regional Investment Opportunity
10.2 Industry Investment Opportunity
PART 11 Coronavirus Impact
11.1 Impact on Industry Upstream
11.2 Impact on Industry Downstream
11.3 Impact on Industry Channels
11.4 Impact on Industry Competition
11.5 Impact on Industry Obtain Employment
Part 12 Conclusion
Continue…
CONTACT US
PH : +(210) 775-2636
0 notes
Last Seen Blogs
v-o-i-d-p-u-n-k
ARSON
shotbygad-blog
Shotbygad
billyblanks
mrsadsonghimself
damntender
𝑫𝑨𝑴𝑵𝑻𝑬𝑵𝑫𝑬𝑹 .
learnpossible
Untitled